Job Location : all cities,ID, USA
XenoSTART, the preclinical division of START is a translational research organization focused on creating relevant preclinical cancer models. Our xenograft models represent each cancer type and disease stage and are established from patients at our domestic and international cancer centers.The XenoSTART Patient-Derived Xenograft (XPDX) platform includes over 2,500 models annotated with each donor patient's cancer treatment and outcome data and characterized using IHC, DNA/RNA sequencing, and relevant in vivo drug efficacy.Our XPDX models are clinically annotated and include patient treatment history and outcome and are characterized through genomic profiling, histologic analysis, and in vivo drug sensitivity to relevant standards of care. These models may be utilized in the following manner:
We are hiring a dynamic and results-driven Director of Business Development to join our team at XenoSTART. As a key player in our sales force, you will be responsible for understanding XenoSTART's unique selling proposition and translating it into effective solutions tailored to each customer's needs. This role requires a keen understanding of the Pre-Clinical sales process along with the ability to manage and exceed performance objectives in an assigned territory or named accounts.
This is a remote role. The annual base salary for this role is $130,000 - $150,000 + Commission. However, base pay may vary depending on multiple individualized factors including market location, job-related knowledge, skills, and experience.Essential Responsibilities
Education & Experience
Preferred Education and Experience:
Physical and Travel Requirements:
Best-in-Class Benefits and PerksWe value our employees' time and efforts. Our commitment to your success is enhanced by a competitive compensation, depending on experience, and an extensive benefits package including:
More about The START Center for Cancer ResearchDeeply rooted in community oncology centers globally, The START Center for Cancer Research provides access to specialized preclinical and early-phase clinical trials of novel anti-cancer agents. START clinical trial sites have conducted more than a thousand early-phase clinical trials, including for 43 therapies that were approved by the FDA. START represents the world's largest roster of Principal Investigators (PIs) across its eight clinical trial sites. Committed to accelerating passage from trials to treatments, START delivers hope to patients, families, and physicians around the world. Learn more atSTARTresearch.com.Ready to be part of a team changing the future of cancer treatment?Join us in our mission to conquer cancer, one clinical trial at a time. Your expertise and dedication can help us bring hope and healing to patients worldwide. Please submit your application online.We are an equal opportunity employer that welcomes and encourages diversity in the workplace. We do not discriminate on the basis of race, color, religion, marital status, age, national origin, ancestry, physical or mental disability, medical condition, pregnancy, genetic information, gender, sexual orientation, gender identity or expression, veteran status, or any other status protected under federal, state, or local law.
#J-18808-Ljbffr